OptiBrand Rx

🚀 PMRC West starts today, and we're ready to meet you.

The OptiBrand Rx team is excited to be onsite and looking forward to connecting with fellow researchers, marketers, and industry leaders throughout the conference.

If you're attending PMRC West, stop by our booth and say hello. We'd love to meet you, learn about your challenges, and share how we're helping brands uncover the unarticulated drivers behind decision-making.

You'll find:

• Chris Arakelian - EVP, Brand Strategy & Growth
• Jessica VandenPlas - Sr. Director of Research
• Rezwan Uddin - Research Specialist

Looking forward to great conversations and new connections.

See you at PMRC West!

Some advances in oncology come from discovering new therapies. Others come from understanding how to unlock the potential of existing science.

Today we recognize ISTODAX® (romidepsin), an epigenetic therapy that helped expand understanding of how targeted modulation of gene expression could be used in the treatment of certain T-cell lymphomas.

As a histone deacetylase (HDAC) inhibitor, ISTODAX represented a different approach to fighting cancer, one focused on influencing the biological mechanisms that drive malignant cells.

Through time, ISTODAX remains an approved treatment option for certain patients with cutaneous T-cell lymphoma and continues to hold an important place in the evolution of epigenetic cancer therapies.

OptiBrand RX is proud to highlight the therapies, innovations, and scientific journeys that continue to shape the future of oncology care.

Learn more: https://www.clfoundation.org/romidepsin-0

Some of the most meaningful breakthroughs in healthcare are the ones that help prevent disease before it has a chance to change a life.

Today we highlight GARDASIL® 9, a vaccine designed to help protect against certain cancers and diseases caused by nine types of human papillomavirus (HPV), including cervical, a**l, and certain head and neck cancers. By focusing on prevention, it represents an important step toward reducing the long-term impact of HPV-related disease.

Behind every vaccination is something bigger than medicine: the possibility of a healthier future, fewer cancer diagnoses, and more years spent with the people who matter most.

OptiBrand RX is proud to spotlight innovations that not only advance science, but also help protect families, communities, and future generations through the power of prevention.

Learn more: https://www.merckvaccines.com/gardasil9/

In metastatic castration-resistant prostate cancer, every additional treatment option matters.

JEVTANA® (cabazitaxel) was developed to support patients whose disease has progressed after prior docetaxel treatment, helping address one of the most complex stages of prostate cancer care. Its approval marked an important advancement for patients facing limited therapeutic options.

OptiBrand RX is proud to support work connected to therapies that continue pushing oncology care forward and expanding possibilities for patients and providers navigating difficult treatment journeys.

Learn more: https://www.jevtana.com/

Today we highlight Yuviwel® (navepegritide), a February 2026 FDA-approved therapy developed to support growth in children living with achondroplasia, the most common form of dwarfism.

As the first once-weekly CNP a**log approved for this condition, Yuviwel represents an important advancement in rare pediatric disease care, helping reduce treatment burden while targeting the underlying biology that affects bone growth.

Why this matters:

• Achondroplasia is a rare genetic condition associated with lifelong skeletal and developmental challenges.
• Treatment adherence can be difficult in chronic pediatric conditions requiring frequent injections.
• Once-weekly administration may help reduce burden while supporting more consistent care routines.

OptiBrand is proud to spotlight innovations that bring new possibilities to underserved patient communities and help improve long-term treatment experiences for children and families.

Learn more: https://yuviwel.com/

Today we highlight VENCLEXTA® (venetoclax), a targeted therapy designed to help treat certain blood cancers, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML).

VENCLEXTA works by targeting the BCL-2 protein, which helps cancer cells survive longer than they should. By blocking this pathway, the therapy helps trigger the natural death of cancer cells, an important shift toward more precise, mechanism-driven oncology care.

Its role in combination regimens for AML and other hematologic malignancies reflects how targeted therapies continue to reshape treatment strategies and expand options for patients navigating complex diagnoses.

OptiBrand recognizes the impact of therapies that move oncology forward through deeper biological understanding and more individualized approaches to care.

Learn more: https://www.venclexta.com/

Today we highlight Zoladex® (goserelin), a hormone therapy that plays a critical role in the treatment of hormone-sensitive cancers and gynecologic conditions.

Zoladex is a GnRH agonist that works by suppressing the production of key hormones like testosterone and estrogen, which are hormones that can fuel the growth of certain cancers. By reducing these levels, it helps slow disease progression at its source.

Used across indications including prostate cancer, breast cancer, and endometriosis, Zoladex represents a well-established approach in endocrine therapy, where targeting hormonal pathways can meaningfully impact outcomes.

In complex treatment landscapes, therapies like Zoladex demonstrate how understanding and intervening in underlying biology can reshape care strategies.

OptiBrand recognizes the importance of innovations that address disease at a foundational level, especially when they expand options for patients navigating long-term, hormone-driven conditions.

Learn more: https://www.zoladex.com/

Today we highlight Odomzo® (sonidegib), a targeted therapy designed to treat locally advanced basal cell carcinoma (BCC) in adults when surgery or radiation are no longer viable options.

Odomzo works by inhibiting the Hedgehog signaling pathway, specifically targeting the Smoothened (SMO) protein, a key driver in the uncontrolled cell growth seen in certain skin cancers. By blocking this pathway, it helps slow or stop tumor progression at a molecular level.

Basal cell carcinoma is often treatable with localized approaches, but for patients with advanced disease, therapeutic options become significantly more limited. Targeted treatments like Odomzo represent the critical shift of moving beyond conventional interventions to address the biology of the disease itself.

OptiBrand values innovations that bring precision to oncology, especially in cases where standard care pathways fall short, and new mechanisms can redefine what’s possible for patients.

Learn more: https://www.odomzo.com/

Today we highlight Xofigo®, a targeted alpha therapy indicated for patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastases.

Xofigo uses an alpha-emitting radioisotope (radium-223) that selectively targets areas of increased bone turnover, delivering localized radiation that induces double-strand DNA breaks in tumor cells while helping limit damage to surrounding tissue.

Bone metastases represent a major clinical challenge in advanced prostate cancer, often contributing to pain, skeletal complications, and reduced survival. Targeted radiopharmaceutical approaches such as Xofigo demonstrate how precision oncology continues to expand beyond traditional systemic therapies.

OptiBrand values innovations that bring targeted mechanisms to complex oncology settings where treatment precision can meaningfully impact patient outcomes.

Learn more: https://www.xofigo.com/